Aloka Amarakone, MD
Neurology · Belleville, ILNPI 1407051329
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,654 and has fallen 97.0% since, to $50 in 2021.
Across 135 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$292
- Supernus Pharmaceuticals, Inc.$199
- Novartis$189
- EMD Serono, Inc.$112
- Lundbeck LLC$110
- Biogen$88
- plus $929 from 26 others
What the payments were for
- Food & beverage$1,919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $292 |
| Supernus Pharmaceuticals, Inc. | 12 | $199 |
| Novartis | 13 | $189 |
| EMD Serono, Inc. | 10 | $112 |
| Lundbeck LLC | 6 | $110 |
| Biogen | 5 | $88 |
| CSL Behring | 3 | $80 |
| GE HealthCare | 4 | $75 |
| Sanofi | 4 | $71 |
| UCB, Inc. | 3 | $64 |
| Amgen | 3 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $42 |
| Medtronic | 3 | $41 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| AstraZeneca | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $27 |
| Adamas Pharmaceuticals, Inc. | 2 | $26 |
| Promius Pharma LLC | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Braemar Manufacturing, LLC | 1 | $13 |
| Aquestive Therapeutics, Inc. | 1 | $11 |
How this compares
$1,919 in reported general payments places this provider in the 65th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Belleville
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.